drugset / Trial / NCT05226442

Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMO

NCT05226442

Phase 2/3 Completed 40 enrolled Medical University of Vienna
RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, randomized, controlled pilot trial aims to assess the safety and feasibility of Argatroban as an alternative anticoagulant to unfractionated heparin in patients receiving extracorporeal membrane oxygenation.

Timeline

Start
2021-12-01
Primary completion
2024-07-07
Completion
2024-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Argatroban Small molecule 0.3 ug/kg
Comparator Heparin Other / unclassified